Desferrioxamine treatment in thalassaemia: A cost utility analysis

M. Dahlui, M. I. Hishamshah, A. Rahman A. Jamal, Khadijah Shamsuddin, Syed Mohamed Al-Junid Syed Junid

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A cost-utility analysis was performed desferrioxamine treatment in thalassaemia patients at two tertiary hospitals in Malaysia in 2004. A hundred and twelve transfusion dependent thalassaemia patients ivere grouped according to tlie status of desferrioxamine optimum and sub-optimum. Cost analysis was from a patient and hospital perspectives while Quality Adjusted Life Years (QALYs) was the health outcome of choice. Incremental Cost-Effectiveness Ratio (ICER) was also stipulated to show the difference in cost for an additional QALY if patient currently on sub-optimum desferrioxamine to switch using optimum des/errioxamine. Results on cost analysis showed the mean cost of treatment for thalassaemia patients on optimum desferrioxamine was higher than those on sub-optimum desferrioxamine (RM14, 775.00+SDRM4,737.00 and RM10,780+RM3,655, respectively). QALYs were 19.186+6.591 and 9.859+5.275 in the optimum and sub-optimum group, respectively. Cost-utility analysis showed the cost per QALYs in optimum des/errioxamine group was RM59.045.00 compared to RM44,665.00 in suboptimum desferrioxamine group. ICER of patients on sub-optimum desferrioxamine switching to optimum desferrioxamine was only RM420.39. Sensitivity analysis showed that the results were robust in the best and worst scenarios. In conclusion, although it is expensive for thalassaemia patients to use optimum desferrioxamine compared to sub-optimum des/errioxamine, the cost per QALYs gained was undoubtedly low.

Original languageEnglish
Pages (from-to)4-9
Number of pages6
JournalMalaysian Journal of Public Health Medicine
Volume7
Issue number2
Publication statusPublished - 2007

Fingerprint

Deferoxamine
Thalassemia
Cost-Benefit Analysis
Quality-Adjusted Life Years
Costs and Cost Analysis
Therapeutics
Malaysia
Tertiary Care Centers
Health Care Costs
Health

Keywords

  • Cost-effectiveness analysis
  • Desferrioxamine treatment
  • QALYs
  • Thalassaemia patients

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Desferrioxamine treatment in thalassaemia : A cost utility analysis. / Dahlui, M.; Hishamshah, M. I.; A. Jamal, A. Rahman; Shamsuddin, Khadijah; Syed Junid, Syed Mohamed Al-Junid.

In: Malaysian Journal of Public Health Medicine, Vol. 7, No. 2, 2007, p. 4-9.

Research output: Contribution to journalArticle

@article{b7d3b555012d477a92434a11d62e0828,
title = "Desferrioxamine treatment in thalassaemia: A cost utility analysis",
abstract = "A cost-utility analysis was performed desferrioxamine treatment in thalassaemia patients at two tertiary hospitals in Malaysia in 2004. A hundred and twelve transfusion dependent thalassaemia patients ivere grouped according to tlie status of desferrioxamine optimum and sub-optimum. Cost analysis was from a patient and hospital perspectives while Quality Adjusted Life Years (QALYs) was the health outcome of choice. Incremental Cost-Effectiveness Ratio (ICER) was also stipulated to show the difference in cost for an additional QALY if patient currently on sub-optimum desferrioxamine to switch using optimum des/errioxamine. Results on cost analysis showed the mean cost of treatment for thalassaemia patients on optimum desferrioxamine was higher than those on sub-optimum desferrioxamine (RM14, 775.00+SDRM4,737.00 and RM10,780+RM3,655, respectively). QALYs were 19.186+6.591 and 9.859+5.275 in the optimum and sub-optimum group, respectively. Cost-utility analysis showed the cost per QALYs in optimum des/errioxamine group was RM59.045.00 compared to RM44,665.00 in suboptimum desferrioxamine group. ICER of patients on sub-optimum desferrioxamine switching to optimum desferrioxamine was only RM420.39. Sensitivity analysis showed that the results were robust in the best and worst scenarios. In conclusion, although it is expensive for thalassaemia patients to use optimum desferrioxamine compared to sub-optimum des/errioxamine, the cost per QALYs gained was undoubtedly low.",
keywords = "Cost-effectiveness analysis, Desferrioxamine treatment, QALYs, Thalassaemia patients",
author = "M. Dahlui and Hishamshah, {M. I.} and {A. Jamal}, {A. Rahman} and Khadijah Shamsuddin and {Syed Junid}, {Syed Mohamed Al-Junid}",
year = "2007",
language = "English",
volume = "7",
pages = "4--9",
journal = "Malaysian Journal of Public Health Medicine",
issn = "1675-0306",
publisher = "Malaysian Public Health Physicians' Association",
number = "2",

}

TY - JOUR

T1 - Desferrioxamine treatment in thalassaemia

T2 - A cost utility analysis

AU - Dahlui, M.

AU - Hishamshah, M. I.

AU - A. Jamal, A. Rahman

AU - Shamsuddin, Khadijah

AU - Syed Junid, Syed Mohamed Al-Junid

PY - 2007

Y1 - 2007

N2 - A cost-utility analysis was performed desferrioxamine treatment in thalassaemia patients at two tertiary hospitals in Malaysia in 2004. A hundred and twelve transfusion dependent thalassaemia patients ivere grouped according to tlie status of desferrioxamine optimum and sub-optimum. Cost analysis was from a patient and hospital perspectives while Quality Adjusted Life Years (QALYs) was the health outcome of choice. Incremental Cost-Effectiveness Ratio (ICER) was also stipulated to show the difference in cost for an additional QALY if patient currently on sub-optimum desferrioxamine to switch using optimum des/errioxamine. Results on cost analysis showed the mean cost of treatment for thalassaemia patients on optimum desferrioxamine was higher than those on sub-optimum desferrioxamine (RM14, 775.00+SDRM4,737.00 and RM10,780+RM3,655, respectively). QALYs were 19.186+6.591 and 9.859+5.275 in the optimum and sub-optimum group, respectively. Cost-utility analysis showed the cost per QALYs in optimum des/errioxamine group was RM59.045.00 compared to RM44,665.00 in suboptimum desferrioxamine group. ICER of patients on sub-optimum desferrioxamine switching to optimum desferrioxamine was only RM420.39. Sensitivity analysis showed that the results were robust in the best and worst scenarios. In conclusion, although it is expensive for thalassaemia patients to use optimum desferrioxamine compared to sub-optimum des/errioxamine, the cost per QALYs gained was undoubtedly low.

AB - A cost-utility analysis was performed desferrioxamine treatment in thalassaemia patients at two tertiary hospitals in Malaysia in 2004. A hundred and twelve transfusion dependent thalassaemia patients ivere grouped according to tlie status of desferrioxamine optimum and sub-optimum. Cost analysis was from a patient and hospital perspectives while Quality Adjusted Life Years (QALYs) was the health outcome of choice. Incremental Cost-Effectiveness Ratio (ICER) was also stipulated to show the difference in cost for an additional QALY if patient currently on sub-optimum desferrioxamine to switch using optimum des/errioxamine. Results on cost analysis showed the mean cost of treatment for thalassaemia patients on optimum desferrioxamine was higher than those on sub-optimum desferrioxamine (RM14, 775.00+SDRM4,737.00 and RM10,780+RM3,655, respectively). QALYs were 19.186+6.591 and 9.859+5.275 in the optimum and sub-optimum group, respectively. Cost-utility analysis showed the cost per QALYs in optimum des/errioxamine group was RM59.045.00 compared to RM44,665.00 in suboptimum desferrioxamine group. ICER of patients on sub-optimum desferrioxamine switching to optimum desferrioxamine was only RM420.39. Sensitivity analysis showed that the results were robust in the best and worst scenarios. In conclusion, although it is expensive for thalassaemia patients to use optimum desferrioxamine compared to sub-optimum des/errioxamine, the cost per QALYs gained was undoubtedly low.

KW - Cost-effectiveness analysis

KW - Desferrioxamine treatment

KW - QALYs

KW - Thalassaemia patients

UR - http://www.scopus.com/inward/record.url?scp=84930067165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930067165&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84930067165

VL - 7

SP - 4

EP - 9

JO - Malaysian Journal of Public Health Medicine

JF - Malaysian Journal of Public Health Medicine

SN - 1675-0306

IS - 2

ER -